Delivery Order SPE2DB20D2001-SPE2DB25FPNHL
- Not listed
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $5,360.72 for Zepbound 7.5 mg/0.5 mL pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitive, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Zepbound 5 mg/0.5 ml pens valued at $3,647.57. This firm fixed-price delivery order, with an ultimate completion date of July 25, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen will perform this work from its corporate office location in Conshohocken, Pennsylvania. The delivery order falls under the company's broader Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Zepbound 5 mg/0.5 mL pens with a ceiling value of $6,208.02. This firm fixed-price delivery order is a non-set-aside award and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The work will be performed at the contractor's corporate...
- The Defense Logistics Agency awarded a $20,902.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Zepbound 5 mg/0.5 mL pens. This contract, which carries an ultimate completion date of July 28, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The delivery order was competitively awarded without set-aside...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $67,987.81 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on July 22, 2025. This firm fixed-price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The place of performance is located in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $1,306.78 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Zepbound 5 mg/0.5 mL pens. This competitive award, with a completion date of July 30, 2025, represents a child delivery order under AmerisourceBergen's broader pharmaceutical supply arrangements with the federal government. The order will be fulfilled from the vendor's Conshohocken, Pennsylvania location, where the company operates as a major...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $29,311.50 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pens on July 21, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside delivery order with an ultimate completion date of July 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under the company's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,151.89 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This firm fixed-price delivery order carries no set-aside designation and represents a competitively awarded transaction under the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December...
- The Defense Logistics Agency awarded a delivery order valued at $2,287.74 to AmerisourceBergen Drug Corp for Zepbound 15 mg/0.5 ml pens on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of pharmaceutical supply services under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Zepbound 2.5 mg/0.5 ml pen injections with a ceiling value of $43,927.89. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is expected to be completed by July 22, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- SPE2DB20D2001Indefinite Delivery Contract
- SPE2DB20D2001-SPE2DB25FPNHLDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 mL pens valued at $4,370.58 on July 29, 2025, with ultimate completion scheduled for July 30, 2025. This firm fixed-price delivery order, which was competitively awarded with no set-aside designation, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a total contract value of $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal military and veteran healthcare procurement through the DLA Medical Supply Chain. The company's extensive portfolio of federal contract awards encompasses a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. This delivery order for Zepbound, a diabetes medication, exemplifies the company's role in supporting Defense Health Agency medical programs and broader federal healthcare systems through flexible contracting vehicles designed to meet diverse pharmaceutical supply requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.4k | 7/29/25 |